Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse MKT  >  ImmunoCellular Therapeutics Ltd    IMUC

Delayed Quote. Delayed  - 09/23 10:02:00 pm
0.1229 USD   +2.08%
09/10 IMMUNOCELLULAR : Imuc) to achieve $1.35 in next 52-weeks
08/22 IMMUNOCELLULAR : Announces Second Quarter 2016 Financial Results
08/17 IMMUNOCELLULAR : to Report Second Quarter 2016 Financial Results on..
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
09/19/2016 09/20/2016 09/21/2016 09/22/2016 09/23/2016 Date
0.121(c) 0.1204(c) 0.1187(c) 0.1204(c) 0.1229(c) Last
1 516 446 1 959 721 1 537 464 1 476 904 1 760 759 Volume
-2.26% -0.50% -1.41% +1.43% +2.08% Change
More quotes
Financials ($)
Sales 2016 0,75 M
EBIT 2016 -22,5 M
Net income 2016 -23,0 M
Debt 2016 -
Yield 2016 -
Sales 2017 2,15 M
EBIT 2017 -23,5 M
Net income 2017 -24,0 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 21,0x
Capi. / Sales2017 7,31x
Capitalization 15,7 M
More Financials
Company
ImmunoCellular Therapeutics Ltd. is a Los Angeles-based clinical-stage company that develops immune-based therapies for the treatment of brain and other cancers.ImmunoCellular's pipeline includes: ICT-121, a dendritic cell immunotherapy targeting the CD133 antigen on stem cells in recurrent... 
More about the company
Latest news on IMMUNOCELLULAR THERAPEUTIC
09/16 IMMUNOCELLULAR THERAPEUTICS, LTD. : Change in Directors or Principal Officers (f..
09/10 IMMUNOCELLULAR THERAPEUTICS, LTD. (N : Imuc) to achieve $1.35 in next 52-weeks
09/01 IMMUNOCELLULAR THERAPEUTICS, LTD. : Notice of Delisting or Failure to Satisfy a ..
09/01 IMMUNOCELLULAR THERAPEUTICS : Announces Second Quarter 2016 Financial Results
08/22 IMMUNOCELLULAR THERAPEUTICS, LTD. : Results of Operations and Financial Conditio..
08/22 IMMUNOCELLULAR THERAPEUTICS : Management's Discussion and Analysis of Financial ..
08/22 IMMUNOCELLULAR THERAPEUTICS : Announces Second Quarter 2016 Financial Results
08/18 IMMUNOCELLULAR THERAPEUTICS : Announces Pricing of $7.4 Million Public Offering
08/17 IMMUNOCELLULAR THERAPEUTICS : to Report Second Quarter 2016 Financial Results on..
08/09 IMMUNOCELLULAR THERAPEUTICS : Announces Pricing of $7.4 Million Public Offering
More news
Sector news : Biotechnology & Medical Research - NEC
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
09/21DJGILEAD SCIENCES : Halts Test of Bowel Disease Treatment
09/20 Bayer raises sales targets for top-selling drugs after Monsanto deal
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
08/22 ImmunoCellular Therapeutics' (IMUC) CEO Andrew Gengos on Q2 2016 Results - Ea..
08/22 ImmunoCellular Therapeutics beats by $0.01
06/07 ImmunoCellular's late-stage study of lead product candidate in glioblastoma c..
05/12 ImmunoCellular Therapeutics' (IMUC) CEO Andrew Gengos on Q1 2016 Results - Ea..
05/12 ImmunoCellular Therapeutics beats by $0.01
Advertisement
Chart IMMUNOCELLULAR THERAPEUTIC
Duration : Period :
ImmunoCellular Therapeutic Technical Analysis Chart | IMUC | US4525361055 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 1,35 $
Spread / Average Target 998%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Andrew Gengos President, Chief Executive Officer & Director
Gary S. Titus Chairman
David E. Fractor Principal Financial & Accounting Officer
Steven J. Swanson Senior Vice President-Research
John S. Yu Secretary & Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOCELLULAR THERAPE..-65.41%16
INCYTE CORPORATION-17.95%16 728
CELLTRION, INC.--.--%11 664
LONZA GROUP AG13.18%10 059
QUINTILES TRANSNATIONA..15.66%9 453
SEATTLE GENETICS, INC.24.40%7 845
More Results